Perché le infezioni fungine delle unghie dei piedi sono resistenti alla guarigione definitiva nella maggior parte dei casi?
Barra laterale dell'articolo
Contenuto principale dell'articolo
Abstract
L'onicomicosi cronica, comune a molti pazienti, è causata principalmente da dermatofiti, lieviti e muffe non dermatofitiche. Circa il 90% dei casi di onicomicosi delle unghie dei piedi è dovuto a dermatofiti, in particolare Trichophyton (T.) rubrum e T. mentagrophytes.
Nonostante la disponibilità di numerosi farmaci antimicotici, fattori complessi come la resistenza ai farmaci, la formazione di biofilm, la scarsa penetrazione del farmaco nell'unghia e le condizioni individuali del paziente rendono difficile una guarigione completa e definitiva.
Questo articolo sottolinea l'importanza di nuovi approcci terapeutici e potenziali direzioni di ricerca, esaminando al contempo le complesse cause della resistenza delle infezioni fungine delle unghie dei piedi al trattamento a lungo termine.
Downloads
Dettagli dell'articolo
Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
Riferimenti bibliografici
Vlahovic TC, Joseph WS, Scher RK, Tosti A, Plasencia J, Pariser DM, et al. Diagnosis and management of onychomycosis perspectives from a joint podiatric medicine-dermatology roundtable. J Am Podiatr Med Assoc. 2016 Mar;106(2):155-62. DOI: 10.7547/14-170.
Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010 Oct;35(5):497-519. DOI: 10.1111/j.1365-2710.2009.01107. x.
Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019 Apr;80(4):853-867. DOI: 10.1016/j.jaad.2018.05.1260.
Pai V, Ganavalli A, Kikkeri NN. Antifungal resistance in dermatology. Indian J Dermatol. 2018 Sep-Oct;63(5):361-368. DOI: 10.4103/ijd.IJD_131_17.
Prajapati SK, Jain A, Bajpai M. Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment. RSC Adv. 2025 Mar 11;15(10):7799-7825. DOI: 10.1039/d5ra00387c.
Bodman MA, Syed HA, Krishnamurthy K. Onychomycosis. StatPearls. Treasure Island Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441853/
The Wall Street Journal. Fatal fungi threaten global health, WHO says. 2022. Available from: https://www.wsj.com/articles/fatal-fungi-threaten-global-health-who-says-11666708805
Gupta AK, Elewski B, Joseph WS, Lipner SR, Daniel CR, Tosti A et al. Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents. Mycoses. 2024;67: e13683. DOI:10.1111/myc.13683.
Ranawaka RR, Nagahawatte A, Gunasekara TA. Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases. Int J Dermatol. 2015 Nov;54(11):1275-82. DOI: 10.1111/ijd.12906.
InformedHealth.org. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Overview: Nail fungus. [Updated 2025 Jul 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279547/
Baswan S, Kasting GB, Li SK, Wickett R, Adams B, Eurich S, et al. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases. Mycoses. 2017 May; 60(5):284-295. DOI: 10.1111/myc.12592.
Desai JV, Mitchell AP, Andes DR. Fungal biofilms, drug resistance, and recurrent infection. Cold Spring Harb Perspect Med. 2014 Oct 1;4(10): a019729. DOI: 10.1101/cshperspect. a019729.
Cutrín Gómez E, Anguiano Igea S, Delgado-Charro MB, Gómez Amoza JL, Otero Espinar FJ. Microstructural alterations in onychomycotic and psoriatic nail: Relevance in drug delivery. Eur J Pharm Biopharm. 2018 Jul; 128:48-56. DOI: 10.1016/j.ejpb.2018.04.012.
Osset-Trénor P, Pascual-Ahuir A, Proft M. Fungal drug response and antimicrobial resistance. J Fungi (Basel). 2023 May 12; 9(5):565. DOI: 10.3390/jof9050565.
Abdullah L, Abbas O. Common nail changes and disorders in older people: Diagnosis and management. Can Fam Physician. 2011 Feb; 57(2):173-81.
Gupta AK, Taylor D, Wang T, Cooper EA, Saunte DML. Hygiene practices against dermatophytic fungi: a review of strategies to combat antifungal resistance. Biology (Basel). 2025 Aug 7;14(8):1016. DOI: 10.3390/biology14081016.
Westerberg DP, Voyack MJ. Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician. 2013 Dec 1;88(11):762-70. PMID: 24364524.
Zaias N, Escovar SX, Zaiac MN, Edwards R, Dutra M, Pona A, et al. Onychomycosis, the active invasion of a normal nail unit by a dermatophytic versus the colonization of an existing abnormal nail unit by environmental fungus. Skinmed. 2020 Jan 1;18(1):18-22. PMID: 32167451.
Sobel JD, Akins R. Determining susceptibility in candida vaginal isolates. Antimicrob Agents Chemother. 2022 Jun 21;66(6): e0236621. DOI: 10.1128/aac.02366-21.
Zhang J, Lin P, Li J, Guo C, Zhai J, Zhang Y. Efficacy of laser therapy combined with topical antifungal agents for onychomycosis: a systematic review and meta-analysis of randomised controlled trials. Lasers Med Sci. 2022 Aug;37(6):2557-2569. DOI: 10.1007/s10103-022-03561-9.
Roy M, Karhana S, Shamsuzzaman M, Khan MA. Recent drug development and treatments for fungal infections. Braz J Microbiol. 2023 Sep;54(3):1695-1716. DOI: 10.1007/s42770-023-00999-z.
Meccatti VM, Santos LF, de Carvalho LS, Souza CB, Carvalho CAT, Marcucci MC, Abu Hasna A, de Oliveira LD. Antifungal action of herbal plants' glycolic extracts against candida species. Molecules. 2023 Mar 22; 28(6):2857. DOI: 10.3390/molecules28062857.
Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16(5-6):327-30. DOI: 10.1080/09546630500420183.
Braný D, Dvorská D, Halašová E, Škovierová H. Cold Atmospheric Plasma: A Powerful Tool for Modern Medicine. Int J Mol Sci. 2020 Apr 22; 21(8):2932. DOI: 10.3390/ijms21082932.
Karthik C, Sarngadharan SC, Thomas V. Low-Temperature Plasma Techniques in Biomedical Applications and Therapeutics: An Overview. Int J Mol Sci. 2023 Dec 30;25(1):524. DOI: 10.3390/ijms25010524.
Shemer A, Daniel R, Kassem R, Geffen Y, Galili E. Cold sub-atmospheric and atmospheric pressure plasma for the treatment of Trichophyton rubrum onychomycosis: An in-vitro study. Dermatol Ther. 2020 Nov;33(6):e14084. DOI: 10.1111/dth.14084.
Wang Y, Abazid A, Badendieck S, Mustea A, Stope MB. Impact of Non-Invasive Physical Plasma on Heat Shock Protein Functionality in Eukaryotic Cells. Biomedicines. 2023 May 18;11(5):1471. DOI: 10.3390/biomedicines11051471.
de Oliveira ACD, Ali S, Corassin CH, Ullah S, Pereira KN, Walsh JL, Hojnik N, de Oliveira CAF. Application of cold atmospheric plasma for decontamination of toxigenic fungi and mycotoxins: a systematic review. Front Microbiol. 2025 Jan 3;15:1502915. DOI: 10.3389/fmicb.2024.1502915.
Bulson JM, Liveris D, Derkatch I, Friedman G, Geliebter J, Park S et al. Non-thermal atmospheric plasma treatment of onychomycosis in an in vitro human nail model. Mycoses. 2020 Feb;63(2):225-232. DOI: 10.1111/myc.13030.
Gnat S, tagowski D, Dylag M, Zielinski J, Studzinski M, Nowakiewicz A. Cold atmospheric pressure plasma (CAPP) as a new alternative treatment method for onychomycosis caused by Trichophyton verrucosum: in vitro studies. Infection. 2021 Dec;49(6):1233-1240. DOI: 10.1007/s15010-021-01691-w.
Pang C, Ibrahim A, Bulstrode NW, Ferretti P. An overview of the therapeutic potential of regenerative medicine in cutaneous wound healing. Int Wound J. 2017 Jun;14(3):450-459. DOI: 10.1111/iwj.12735.
Ahn HJ, Kim TE, Lee YJ, Jeong SJ, Shin MK, Jeong KH. A pilot study of semiquantitative treatment evaluation following nonthermal atmospheric-pressure plasma administration for onychomycosis. Skin Res Technol. 2023 Jan;29(1):e13263. DOI: 10.1111/srt.13263.
Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. J Am Acad Dermatol. 2019 Apr;80(4):835-851. DOI: 10.1016/j.jaad.2018.03.062.
Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012 May;54(9):1322-31. DOI: 10.1093/cid/cis132.
Nazary Abrbekoh F, Salimi L, Saghati S, Amini H, Fathi Karkan S, Moharamzadeh K, Sokullu E, Rahbarghazi R. Application of microneedle patches for drug delivery; doorstep to novel therapies. J Tissue Eng. 2022 Apr 29; 13:20417314221085390. DOI: 10.1177/20417314221085390.
Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, López-Ribot JL. Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013 Oct;13(5):726-30. DOI: 10.1016/j.coph.2013.08.008.
Dominguez JAJ, Luque-Vilca OM, Mallma NES, FLores DDC, Zea CYH, Huayhua LLA, Lizárraga-Gamarra FB, Cáceres CGM, Yauricasa-Tornero SV, Paricanaza-Ticona DC, Cajavilca HLV. Antifungal chemicals promising function in disease prevention, method of action and mechanism. Braz J Biol. 2024 Feb 23;83:e275055. DOI: 10.1590/1519-6984.275055.
Ahmed R, Hoque M, Hasan MN. Scabies Prevalence and Management in Bangladesh: A Narrative Review. Bangladesh J Infect Dis 2025;12(1):151-158. DOI: 10.3329/bjid.v12i1.83987.
Vitiello A, Ferrara F, Boccellino M, Ponzo A, Cimmino C, Comberiati E, Zovi A, Clemente S, Sabbatucci M. Antifungal Drug Resistance: An Emergent Health Threat. Biomedicines. 2023 Mar 31;11(4):1063. DOI: 10.3390/biomedicines11041063.
Chinese Burn Association, the Yangtze River Delta Integrated Diabetic Foot Alliance, and the Editorial Committee of the Chinese Journal of Burns and Wound Repair; Luo G, Liu Y, Wang A. Practical guidelines for the prevention and management of diabetic foot disease in China. Burns Trauma. 2025 Nov 11;13:tkaf064. doi: 10.1093/burnst/tkaf064.
Metelko Z, Brkljacic Crkvencic N. Prevencija dijabetickog stopala [Prevention of diabetic foot]. Acta Med Croatica. 2013 Oct;67 Suppl 1:35-44. Croatian. PMID: 24371974.
Hoque M. New Detection of Reovirus in Humans in Bangladesh: A Potential Zoonotic Concern. Bangladesh J Infect Dis 2025;12(1):181-184. DOI: 10.3329/bjid.v12i1.83988.